Jie 2008.

Methods	Allocation: randomised, random number table. Blindness: unclear. Duration: eight weeks. Design: parallel. Setting: inpatient, China.
Participants	Diagnosis: schizophrenia (CCMD‐3), PANSS of 60 or more, SANS of 60 or more. N = 50. Age: aripiprazole group: 18～50 years, mean = (25.7 ± 5.8) years; clozapine group: 18～57 years, mean = (27.85 ± 5.75) years. Gender: aripiprazole group: 16 male, 9 female; clozapine group: 15 male, 10 female. History: aripiprazole group: 1～10 years, mean = (4.15 ± 3.14) years; clozapine group: 1～11years, mean = (4.18 ± 3.15) years. Age at onset not reported.
Interventions	1. Aripiprazole: Dose range: 5‐25 mg/day. Mean = (13.5 ± .8) mg/d. N = 25. 2. Clozapine: Dose range: 50‐500 mg/day. Mean = (385.5 ± 75.5) mg/d. N = 25.
Outcomes	Global state: PANSS score decreased rate(recovery: ≥ 80%, markedly improved: 50%‐75%, improved: 25%‐50%, no effect: < 25). Mental state: PANSS total score, PANSS positive subscale score, PANSS negative subscale score, PANSS general pathological subscale score. Adverse effects: TESS total score.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomised, random number table.
Allocation concealment (selection bias)	Unclear risk	Not reported.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not reported.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Unclear if outcome was assessed blindly.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No incomplete data.
Selective reporting (reporting bias)	High risk	Data on somnolence, weight gain, EGG abnormal, salivation, dry mouth, blurred vision (no data) and use of alprazolam, propranolol, anticholinergic medication were missing.
Other bias	Low risk	None obvious.